Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Calithera Biosci Com (CALA)

2.7   0.01 (0.37%) 03-07 04:12
Open: 2.69 Pre. Close: 2.69
High: 2.72 Low: 2.3838
Volume: 1,474,953 Market Cap: 191M
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.726 - 2.744 2.744 - 2.761
Low: 2.34 - 2.361 2.361 - 2.379
Close: 2.664 - 2.701 2.701 - 2.734

Technical analysis

as of: 2021-03-05 5:05:57 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 3.47     One year: 3.90
Support: Support1: 2.38    Support2: 1.98
Resistance: Resistance1: 2.97    Resistance2: 3.34
Pivot: 2.97
Moving Average: MA(5): 2.80     MA(20): 3.03
MA(100): 3.84     MA(250): 4.52
MACD: MACD(12,26): -0.15     Signal(9): -0.13
Stochastic oscillator: %K(14,3): 18.58     %D(3): 17.62
RSI: RSI(14): 31.93
52-week: High: 8.18  Low: 2.38  Change(%): -51.9
Average Vol(K): 3-Month: 180904  10-Days: 130430

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CALA has closed above bottom band by 9.5%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to CALA's normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 02 Mar 2021
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference - Yahoo Finance

Mon, 22 Feb 2021
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance

Mon, 22 Feb 2021
Calithera Biosciences, Inc. (NASDAQ:CALA) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Wed, 13 Jan 2021
Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options - Yahoo Finance

Mon, 04 Jan 2021
Why Calithera Biosciences Stock Is Plunging Today - Motley Fool

Mon, 28 Dec 2020
Our Take On Calithera Biosciences' (NASDAQ:CALA) CEO Salary - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 71
Shares Float (M) 62
% Held by Insiders 0.72
% Held by Institutions 81.73
Shares Short (K) 3,570
Shares Short P. Month (K) 2,020

Stock Financials

EPS -1.375
EPS Est This Year -0.810
EPS Est Next Year -1.050
Book Value (p.s.) 1.740
Profit Margin
Operating Margin
Return on Assets (ttm) -38.8
Return on Equity (ttm) -73.4
Qtrly Rev. Growth
Gross Profit (p.s.) -1.081
Sales Per Share
EBITDA (p.s.) -1.287
Qtrly Earnings Growth
Operating Cash Flow (M) -80
Levered Free Cash Flow (M) -47

Stock Valuations

PE Ratio -1.96
PEG Ratio
Price to Book value 1.55
Price to Sales
Price to Cash Flow -2.39

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.